Rhythm Pharmaceuticals gets FDA approval for Setmelanotide (IMCIVREE) for Chronic Weight Management in Patients with Obesity due to POMC, PCSK1 or LEPR Deficiency (Age 6 and older). The management team also gave pricing information, indicating $330/mg and blended pricing estimate of $290-300K/patient/year. The stock rose about 21% on this news and I discuss the implications and future catalysts.
Anavex's ANAVEX2-73 (Blarcamesine) is being investigated for Alzheimer's Disease, Parkinson's Disease and Rett Syndrome. I go through the latest data and catalysts that are approaching for the company.
I also touch on $HEPA's latest press releases.
If you want to help out the show (or join the discord), take a look at my patreon: [ Ссылка ]
Follow me on twitter @matthewlepoire
Send me an email matthewlepoire@gmail.com
www.breakingbiotech.com #breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
